Oric Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 100
- Market Cap
- $704.7M
- Website
- http://www.oricpharma.com
- Introduction
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Effect of Food on the Pharmacokinetics of ORIC-114
- Conditions
- Food Effect in Healthy Participants
- Interventions
- Drug: ORIC-114
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT06012721
- Locations
- 🇦🇺
Nucleus Network Pty Ltd., 235 Ryrie St, Geelong, Victoria, Australia
🇦🇺Nucleus Network Pty Ltd., Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, Victoria, Australia
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05413421
- Locations
- 🇺🇸
South Florida Oncology and Hematology, Plantation, Florida, United States
🇺🇸First Urology, Jeffersonville, Indiana, United States
🇺🇸University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Conditions
- Solid Tumors
- Interventions
- Drug: ORIC-114Drug: Chemotherapy drug
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT05315700
- Locations
- 🇺🇸
City of Hope, Long Beach, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Drug: ORIC-533
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT05227144
- Locations
- 🇨🇦
Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario, Canada
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Study of ORIC-101 in Combination With Enzalutamide
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: ORIC-101Drug: enzalutamide 40 MG oral capsule [Xtandi]
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT04033328
- Locations
- 🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of ORIC-101 in Combination With Anticancer Therapy
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT03928314
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: ORIC-101
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03835637
- Locations
- 🇬🇧
Research Center, Nottingham, United Kingdom
Study of ORIC-101 in Healthy Adult Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: ORIC-101
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03324555
- Locations
- 🇺🇸
Research Center, Miami, Florida, United States